Claims for Patent: 6,019,980

Summary for Patent: 6,019,980

Title:	Nucleic acid respiratory syncytial virus vaccines
Abstract:	Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
Inventor(s):	Li; Xiaomao (Thornhill, CA), Ewashysyn; Mary E. (Willowdale, CA), Klein; Michel H. (Willowdale, CA)
Assignee:	Connaught Laboratories Limited (Willowdale, CA)
Application Number:	08/476,397
Patent Claims:	1. An immunogenic composition for in vivo administration to a host for the generation in the host of protective antibodies to RSV F protein, comprising a plasmid vector comprising: a first nucleotide sequence encoding a RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein; a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein in the host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence and comprising a pair of splice sites to prevent aberrant mRNA splicing and to increase expression of said RSV F protein in vivo from said vector in the host, and a pharmaceutically acceptable carrier. 2. The composition of claim 1 wherein said first nucleotide sequence encodes a full-length RSV F protein. 3. The composition of claim 1 wherein said first nucleotide sequence encodes a RSV F protein from which the transmembrane region is absent. 4. The composition of claim 1 wherein said first nucleotide sequence encodes a RSV F protein and contains a translational stop codon immediately upstream of the start of the transmembrane coding region to prevent translation of the transmembrane coding region. 5. The composition of claim 1 wherein said promoter sequence is a immediate early cytomegalovirus promoter. 6. The composition of claim 1 wherein said second nucleotide sequence is that of rabbit .beta.-globin intron II. 7. The composition of claim 1 wherein the plasmid vector is pXL2 as shown in FIG. 5. 8. The composition of claim 1 wherein the plasmid vector is pXL4 as shown in FIG. 7. 9. The composition of claim 1 wherein the plasmid vector is pXL1 as shown in FIG. 4. 10. The composition of claim 1 wherein the plasmid vector is pXL3 as shown in FIG. 6.

Details for Patent 6,019,980

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26